A hybrid effectiveness-implementation trial is a study designed from the outset to answer two questions at once: does an intervention produce the clinical or public-health outcome it is meant to produce, and how well can it actually be delivered in real-world practice settings. Rather than running a clinical effectiveness trial first and waiting years for a separate implementation study to follow, a hybrid design collects effectiveness data and implementation data concurrently, within a single protocol. For research administrators supporting investigator teams that work across clinical trials and health-services or implementation science, hybrid designs are increasingly the framework a funder or protocol will reference by name, so understanding the typology and its practical consequences for staffing, outcomes, and IRB review is directly useful.
Where the typology comes from
The now-standard framework was proposed by Geoffrey Curran and colleagues in a 2012 paper in Medical Care, ‘Effectiveness-Implementation Hybrid Designs: Combining Elements of Clinical Effectiveness and Implementation Research to Enhance Public Health Impact.’ The paper argued that pursuing effectiveness and implementation research strictly sequentially — proving an intervention works, then only afterward studying how to implement it — was slowing translation of research into practice, and proposed three hybrid design types that blend the two lines of inquiry in a single study to varying degrees. The paper has been highly influential in implementation science and has been cited well over 2,000 times since publication; a 2022 ten-year reflection on the framework in Frontiers in Health Services documents how widely the three hybrid types have since been adopted and adapted across fields.
The three hybrid types
The typology is organized around where a study’s primary emphasis sits on a spectrum running from clinical effectiveness at one end to implementation at the other. None of the three types ignores either dimension — the defining feature of a hybrid design is that both are assessed in the same study — but they differ in which one is powered as the primary aim and which is treated as secondary or exploratory.
Type I: effectiveness-primary
A Type I hybrid design tests the clinical effect of an intervention as the primary aim, while simultaneously gathering information on the delivery context — barriers, facilitators, fidelity, and acceptability — that will matter for future implementation. The implementation data collected is typically descriptive or exploratory rather than powered to detect a difference between implementation strategies. Type I is the closest of the three to a conventional effectiveness or pragmatic trial, with an implementation-science evaluation layered on top rather than built into the primary hypothesis.
Type II: dual-primary
A Type II hybrid design gives roughly equal weight to a clinical/effectiveness aim and an implementation aim, and is typically powered to test both. A common Type II structure evaluates the clinical intervention while simultaneously testing an implementation strategy (for example, comparing standard training against an enhanced facilitation strategy for getting clinicians to deliver the intervention as intended). This is generally the most resource- and design-intensive of the three types, because it requires a protocol, sample size, and analysis plan that can support two co-primary questions rather than one.
Type III: implementation-primary
A Type III hybrid design treats an implementation strategy as the primary aim — for example, testing whether a particular training, facilitation, or system-level strategy increases uptake or fidelity of an already-effective intervention — while collecting clinical or patient-level outcome data as a secondary aim to confirm the intervention is still performing as expected in the new delivery context. Type III designs are typically used for interventions that already have a reasonably strong effectiveness evidence base, where the open question is less ‘does it work’ and more ‘how do we get it delivered consistently and at scale.’
Choosing between the three types
The choice is driven mainly by how much effectiveness evidence already exists for the intervention:
- Strong prior effectiveness evidence, little known about real-world delivery — a Type III design is usually the better fit, since the remaining scientific uncertainty is about implementation, not clinical benefit.
- Promising but not yet definitive effectiveness evidence — a Type I design lets a team continue to establish the clinical case while still generating usable implementation intelligence for later.
- Reasonable effectiveness signal plus a genuine open question about which implementation strategy works best — a Type II design is appropriate, accepting the added complexity of powering for two aims.
Funders and reviewers increasingly expect an explicit justification for which hybrid type was selected and why, tied to the existing evidence base for the intervention — treating the choice as a design decision to be defended in the protocol, not a label applied after the fact.
Implementation outcomes are not the same as clinical outcomes
A defining feature of hybrid trials is that they specify true implementation outcomes as endpoints, separate from clinical effectiveness endpoints. Implementation science commonly organizes these around constructs such as acceptability, adoption, appropriateness, feasibility, fidelity, implementation cost, penetration/reach, and sustainability — distinct from a clinical trial’s usual efficacy or safety endpoints. Protocols frequently also draw on complementary implementation science frameworks, such as RE-AIM (Reach, Effectiveness, Adoption, Implementation, Maintenance) or the Consolidated Framework for Implementation Research (CFIR), to structure which implementation-side data are collected and how they are analyzed. A protocol and statistical analysis plan for a hybrid trial should specify implementation outcomes with the same rigor as clinical outcomes — including how they are measured, at what timepoints, and (for Type II designs especially) how the study is powered to detect a meaningful difference in them.
Practical implications for research administration
Hybrid designs have consequences that extend beyond study design into how a trial is staffed, budgeted, and reviewed:
- Mixed-methods capacity. Implementation outcomes are frequently assessed through qualitative or mixed-methods approaches — clinician interviews, fidelity checklists, administrative process data — alongside the trial’s quantitative clinical data collection, which means the study team typically needs both quantitative biostatistics support and qualitative/implementation-science expertise.
- IRB and consent complexity. A hybrid protocol may involve data collection from clinicians, administrators, or organizational units in addition to patient participants, which can raise separate human-subjects considerations beyond a standard clinical protocol and should be flagged to the IRB early rather than assumed to be covered by the clinical consent process alone.
- Budgeting for two data streams. Effectiveness and implementation data collection often run on different timelines and require different staff time (clinical coordinators versus implementation-science research staff), which should be reflected explicitly in the budget and personnel effort rather than folded into a single generic ‘data collection’ line.
- Reporting. Hybrid trials generally require reporting against both clinical trial standards and implementation-science reporting conventions (such as the frameworks implementation outcomes are drawn from), which downstream affects what a data management plan and statistical analysis plan need to specify.
How hybrid designs relate to pragmatic and adaptive trials
Hybrid effectiveness-implementation designs are a distinct concept from, though sometimes combined with, other clinical trial design approaches a research administrator will also encounter. A pragmatic trial is designed to test an intervention under real-world conditions to inform a practical decision, which can make it a natural chassis for a hybrid design — a pragmatic effectiveness trial with implementation outcomes layered on is a common way Type I and Type II hybrids are actually built. Hybrid designs are also conceptually distinct from adaptive clinical trial designs, which pre-specify rules for modifying a trial’s conduct based on accumulating data; a hybrid trial can use an adaptive or a fixed design for its clinical component, since ‘hybrid’ describes the effectiveness/implementation blend rather than the statistical adaptation strategy. See also how quality-by-design planning under ICH E8(R1) intersects with GCP conduct requirements when a hybrid protocol involves both clinical and implementation-focused data collection streams.
Frequently asked questions
What is a hybrid effectiveness-implementation trial design?
It is a clinical study designed to test both whether an intervention produces its intended clinical or public-health effect and how well it can be implemented in real-world practice, collecting effectiveness and implementation data within a single study rather than in two sequential studies.
What’s the difference between Type I, Type II, and Type III hybrid designs?
Type I prioritizes the clinical effectiveness aim while gathering exploratory implementation data. Type II gives roughly equal, typically co-powered, weight to a clinical aim and an implementation aim. Type III prioritizes an implementation strategy as the primary aim while confirming clinical outcomes as a secondary aim, for interventions with an already-established effectiveness evidence base.
What are implementation science outcomes, and how do they differ from clinical outcomes?
Implementation outcomes measure how well an intervention is being delivered rather than what clinical effect it produces — common constructs include acceptability, adoption, fidelity, feasibility, cost, reach/penetration, and sustainability. They are specified and measured separately from, and in addition to, a trial’s clinical effectiveness or safety endpoints.
Who proposed the hybrid design typology?
Geoffrey Curran and colleagues, in a 2012 paper in Medical Care titled ‘Effectiveness-Implementation Hybrid Designs.’ The framework has since become a standard reference point in implementation science and has been widely cited and adopted across health services research.
How do I decide which hybrid type fits my study?
The main driver is how much effectiveness evidence already exists for the intervention. Little-to-moderate evidence generally favors Type I or Type II; a well-established effectiveness base with an open implementation question generally favors Type III. Funders and IRBs typically expect this reasoning stated explicitly in the protocol.
